Under conditions of anemia and hypoxia, erythropoietin (EPO) production is markedly activated in the kidneys to compensate for RBC hemolysis leading to bone marrow expansion, skeletal changes, and hepatosplenomegaly (Rivella, 2012; Rivella, 2019). This evidence concerns the gene EPO and anemia.